CAMBRIDGE, MA—Alnylam Pharmaceuticals has signed on with BioMed Realty Trust for a 295,000 square foot lease at 675 West Kendall in Cambridge, a class A laboratory and office space in Kendall Square.

Alnylam is leading the translation of RNA interference (RNAi), as a new class of innovative medicines, with a core focus on RNAi therapeutics toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options. This growing life science company will occupy all the rentable space available on the six floors of 675 West Kendall when the lease with the current tenant, Vertex Pharmaceuticals, ends in May 2018.

"BioMed Realty has built our business on helping life science companies be successful by providing the laboratory and office platform for companies like Alnylam to conduct breakthrough science that help patients throughout the world," said Bill Kane, SVP for BioMed Realty. "We will welcome Alnylam to their new home, and provide them our unique real estate expertise to ensure they have the best facility to create life-changing treatments for patients." 

Since the beginning of the year, BioMed Realty has signed new leases in Kendall Square and East Cambridge aggregating almost 500,000 square feet, reflecting the demand and vitality of the largest life science urban center in the world.

As a tenant at 675 West Kendall, Alnylam employees will have the benefit of engaging in an amenity-rich, privately owned and operated 10-acre mixed use site that offers top-quality restaurants, kayak and canoe rentals, ice skating, outdoor concerts, and a farmers market.

BioMed Realty specializes in real estate solutions for biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry.